Cargando…
c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients
Purpose: c-MYC has been noted in many tumor types, but its functional significance and clinical utility in oral squamous cell carcinoma (OSCC) are not well known. Here we studied the expression of c-MYC in correlation to clinical outcome in patients with oral squamous cell carcinoma. Methods: The cu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556540/ https://www.ncbi.nlm.nih.gov/pubmed/31239771 http://dx.doi.org/10.2147/CMAR.S201943 |
_version_ | 1783425345771274240 |
---|---|
author | Lin, Shu-Hui Wang, Hsin-Kai Yeh, Kun-Tu Tai, Hui-Chun Wang, Hui-Yi Huang, Lan-Ru Chiu, Chun-Wen Chung, Chia-Min Velmurugan, Bharath Kumar |
author_facet | Lin, Shu-Hui Wang, Hsin-Kai Yeh, Kun-Tu Tai, Hui-Chun Wang, Hui-Yi Huang, Lan-Ru Chiu, Chun-Wen Chung, Chia-Min Velmurugan, Bharath Kumar |
author_sort | Lin, Shu-Hui |
collection | PubMed |
description | Purpose: c-MYC has been noted in many tumor types, but its functional significance and clinical utility in oral squamous cell carcinoma (OSCC) are not well known. Here we studied the expression of c-MYC in correlation to clinical outcome in patients with oral squamous cell carcinoma. Methods: The current study, using immunohistochemical staining, first examined c-MYC expression in OSCC patients and further correlated its expression with clinicopathological parameters. Results: c-MYC was expressed in the majority of OSCC patients (n=133). The c-MYC expression is associated with histological grade (P=0.0205) of patients with oral squamous cell carcinoma. Multivariate Cox regression analysis revealed that TN stage (P<0.001), American Joint Committee on Cancer (AJCC) stage (P<0.0001), and tumor differentiation (P=0.0025) were independent factors for overall survival in patients with OSCC except for c-MYC expression (P>0.05). Multiplicative-scale interaction between T stage (III/IV) and low c-MYC expression on mortality risk was identified (P=0.0233). Kaplan–Meier survival analysis demonstrated that oral cancer patients (T III/IV stage) with high c-MYC expression had better survival than those with low and medium c-MYC expression (P=0.0270). Conclusion: Our data indicate that c-MYC is a potential biomarker that can be used as a therapeutic target for treating OSCC patients with T stage (III/IV). |
format | Online Article Text |
id | pubmed-6556540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65565402019-06-25 c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients Lin, Shu-Hui Wang, Hsin-Kai Yeh, Kun-Tu Tai, Hui-Chun Wang, Hui-Yi Huang, Lan-Ru Chiu, Chun-Wen Chung, Chia-Min Velmurugan, Bharath Kumar Cancer Manag Res Original Research Purpose: c-MYC has been noted in many tumor types, but its functional significance and clinical utility in oral squamous cell carcinoma (OSCC) are not well known. Here we studied the expression of c-MYC in correlation to clinical outcome in patients with oral squamous cell carcinoma. Methods: The current study, using immunohistochemical staining, first examined c-MYC expression in OSCC patients and further correlated its expression with clinicopathological parameters. Results: c-MYC was expressed in the majority of OSCC patients (n=133). The c-MYC expression is associated with histological grade (P=0.0205) of patients with oral squamous cell carcinoma. Multivariate Cox regression analysis revealed that TN stage (P<0.001), American Joint Committee on Cancer (AJCC) stage (P<0.0001), and tumor differentiation (P=0.0025) were independent factors for overall survival in patients with OSCC except for c-MYC expression (P>0.05). Multiplicative-scale interaction between T stage (III/IV) and low c-MYC expression on mortality risk was identified (P=0.0233). Kaplan–Meier survival analysis demonstrated that oral cancer patients (T III/IV stage) with high c-MYC expression had better survival than those with low and medium c-MYC expression (P=0.0270). Conclusion: Our data indicate that c-MYC is a potential biomarker that can be used as a therapeutic target for treating OSCC patients with T stage (III/IV). Dove 2019-06-05 /pmc/articles/PMC6556540/ /pubmed/31239771 http://dx.doi.org/10.2147/CMAR.S201943 Text en © 2019 Lin et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lin, Shu-Hui Wang, Hsin-Kai Yeh, Kun-Tu Tai, Hui-Chun Wang, Hui-Yi Huang, Lan-Ru Chiu, Chun-Wen Chung, Chia-Min Velmurugan, Bharath Kumar c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients |
title | c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients |
title_full | c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients |
title_fullStr | c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients |
title_full_unstemmed | c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients |
title_short | c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients |
title_sort | c-myc expression in t (iii/iv) stage oral squamous cell carcinoma (oscc) patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556540/ https://www.ncbi.nlm.nih.gov/pubmed/31239771 http://dx.doi.org/10.2147/CMAR.S201943 |
work_keys_str_mv | AT linshuhui cmycexpressionintiiiivstageoralsquamouscellcarcinomaosccpatients AT wanghsinkai cmycexpressionintiiiivstageoralsquamouscellcarcinomaosccpatients AT yehkuntu cmycexpressionintiiiivstageoralsquamouscellcarcinomaosccpatients AT taihuichun cmycexpressionintiiiivstageoralsquamouscellcarcinomaosccpatients AT wanghuiyi cmycexpressionintiiiivstageoralsquamouscellcarcinomaosccpatients AT huanglanru cmycexpressionintiiiivstageoralsquamouscellcarcinomaosccpatients AT chiuchunwen cmycexpressionintiiiivstageoralsquamouscellcarcinomaosccpatients AT chungchiamin cmycexpressionintiiiivstageoralsquamouscellcarcinomaosccpatients AT velmuruganbharathkumar cmycexpressionintiiiivstageoralsquamouscellcarcinomaosccpatients |